Clinical Trial Update: A Study of Apabetalone in Subjects With Long -COVID [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update indicates that apabetalone is being studied in Phase 2/Phase 3 for Post-Acute COVID-19 Syndrome and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute COVID-19 Syndrome

Drugs mentioned

• Apabetalone (RVX208) (apabetalone)

Snippet

Sponsor: Resverlogix Corp | Conditions: Post-Acute COVID-19 Syndrome | Phase 2, Phase 3 | Status: RECRUITING